Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free ...

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

Johnson & Johnson JNJ announced that it has submitted a type II variation application to the European Medicines Agency (EMA) seeking approval for the expanded use of Tecvayli (teclistamab). The ...

Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...

Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, ...

Credit: Johnson & Johnson. The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, placebo-controlled, phase 4 TRD4005 trial. Spravato ...

Despite current guidelines recommending combination therapy, there are certain patients with pulmonary arterial hypertension (PAH) who remain on monotherapy for specific reasons. Despite the ...

The efficacy of P2Y12 monotherapy depends on the type of drug used after discontinuation of dual antiplatelet therapy (DAPT) for post-PCI patients, according to a new patient-level meta-analysis.

Please provide your email address to receive an email when new articles are posted on . Dolutegravir monotherapy was safe and noninferior vs. combination ART. Switching to monotherapy from combination ...